290 related articles for article (PubMed ID: 12271292)
21. Juvenile dermatomyositis associated with autoantibodies to small ubiquitin-like modifier activating enzyme: a report of 4 cases from North India and a review of literature.
Vignesh P; Barman P; Basu S; Mondal S; Ishran B; Kumrah R; Dod A; Garg R; Rawat A; Singh S
Immunol Res; 2023 Feb; 71(1):112-120. PubMed ID: 36278969
[TBL] [Abstract][Full Text] [Related]
22. Juvenile dermatomyositis in South African children is characterised by frequent dystropic calcification: a cross sectional study.
Faller G; Mistry BJ; Tikly M
Pediatr Rheumatol Online J; 2014 Jan; 12():2. PubMed ID: 24397895
[TBL] [Abstract][Full Text] [Related]
23. Clinical course and outcomes of Iranian children with juvenile dermatomyositis and polymyositis.
Malek A; Raeeskarami SR; Ziaee V; Aghighi Y; Moradinejad MH
Clin Rheumatol; 2014 Aug; 33(8):1113-8. PubMed ID: 24878926
[TBL] [Abstract][Full Text] [Related]
24. [Calcinosis of childhood dermatomyositis. Apropos of 10 cases].
Bruguier A; Texier P; Sluzewski W; Ponsot G; Arthuis M
Helv Paediatr Acta; 1984 Mar; 39(1):47-54. PubMed ID: 6724996
[TBL] [Abstract][Full Text] [Related]
25. [Juvenile amyopathic dermatomyositis and calcinosis].
Escorial Briso-Montiano M; Solís Sánchez P; Baeza Velasco M; Alonso Rubio A; de Gregorio Alvarez Z
An Pediatr (Barc); 2005 Mar; 62(3):286-8. PubMed ID: 15737292
[TBL] [Abstract][Full Text] [Related]
26. Juvenile dermatomyositis: clinical profile and disease course in 25 patients.
Shehata R; al-Mayouf S; al-Dalaan A; al-Mazaid A; al-Balaa S; Bahabri S
Clin Exp Rheumatol; 1999; 17(1):115-8. PubMed ID: 10084045
[TBL] [Abstract][Full Text] [Related]
27. Local injection of infliximab into calcinosis lesions in patients with juvenile dermatomyositis (JDM): a clinical trial.
Shiari R; Khalili M; Zeinali V; Shashaani N; Samami M; Moghaddamemami FH
Pediatr Rheumatol Online J; 2024 Jan; 22(1):2. PubMed ID: 38166943
[TBL] [Abstract][Full Text] [Related]
28. Comparison of clinical and laboratory features and treatment responses in patients with clinically amyopathic juvenile dermatomyositis and classical juvenile dermatomyositis.
Gezgin Yıldırım D; Baglan E; Güngörer V; Yıldız C; Tuncez S; Bülbül M; Acar B; Bakkaloğlu SA
Int J Rheum Dis; 2023 Aug; 26(8):1504-1511. PubMed ID: 37288472
[TBL] [Abstract][Full Text] [Related]
29. [Polymyositis and dermatomyositis in childhood].
Rodríguez Núñez A; Fernández Bustillo JM; Rodríguez Pérez E; Novo Rodríguez I; Pérez Becerra E; Peña Guitián J; Castro Gago M
An Esp Pediatr; 1988 Oct; 29(4):288-92. PubMed ID: 3069018
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcomes in juvenile dermatomyositis.
Ramanan AV; Feldman BM
Curr Opin Rheumatol; 2002 Nov; 14(6):658-62. PubMed ID: 12410087
[TBL] [Abstract][Full Text] [Related]
31. Early Abnormal Nailfold Capillary Changes Are Predictive of Calcinosis Development in Juvenile Dermatomyositis.
Nozawa T; Bell-Peter A; Marcuz JA; Whitney K; Vinik O; Shupak R; Dover S; Feldman BM
J Rheumatol; 2022 Nov; 49(11):1250-1255. PubMed ID: 35914785
[TBL] [Abstract][Full Text] [Related]
32. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification.
Bowyer SL; Blane CE; Sullivan DB; Cassidy JT
J Pediatr; 1983 Dec; 103(6):882-8. PubMed ID: 6644423
[TBL] [Abstract][Full Text] [Related]
33. Double trouble: therapeutic challenges in patients with both juvenile dermatomyositis and psoriasis.
Kim NN; Lio PA; Morgan GA; Jarvis JN; Pachman LM
Arch Dermatol; 2011 Jul; 147(7):831-5. PubMed ID: 21422326
[TBL] [Abstract][Full Text] [Related]
34. Characteristics and outcome of children with juvenile dermatomyositis in Cape Town: a cross-sectional study.
Okong'o LO; Esser M; Wilmshurst J; Scott C
Pediatr Rheumatol Online J; 2016 Nov; 14(1):60. PubMed ID: 27835954
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate.
Al-Mayouf S; Al-Mazyed A; Bahabri S
Clin Rheumatol; 2000; 19(2):138-41. PubMed ID: 10791626
[TBL] [Abstract][Full Text] [Related]
36. Clinical features and outcome in a Danish cohort of juvenile dermatomyositis patients.
Mathiesen PR; Zak M; Herlin T; Nielsen SM
Clin Exp Rheumatol; 2010; 28(5):782-9. PubMed ID: 21029565
[TBL] [Abstract][Full Text] [Related]
37. [Juvenile dermatomyositis].
Dressler F; Huppertz HI
Z Rheumatol; 2006 Nov; 65(7):587-90, 592-4. PubMed ID: 17051362
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of probenecid for a patient with juvenile dermatomyositis complicated with calcinosis.
Nakamura H; Kawakami A; Ida H; Ejima E; Origuchi T; Eguchi K
J Rheumatol; 2006 Aug; 33(8):1691-3. PubMed ID: 16881125
[TBL] [Abstract][Full Text] [Related]
39. Early-onset juvenile dermatomyositis: A tertiary referral center experience and review of the literature.
Sener S; Basaran O; Batu ED; Sag E; Oz S; Talim B; Bilginer Y; Haliloglu G; Ozen S
Semin Arthritis Rheum; 2023 Feb; 58():152133. PubMed ID: 36434896
[TBL] [Abstract][Full Text] [Related]
40. Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset.
Sanner H; Gran JT; Sjaastad I; Flatø B
Rheumatology (Oxford); 2009 Dec; 48(12):1541-7. PubMed ID: 19776224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
